𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Gemcitabine and Docetaxel in patients with advanced solid tumors. A GETICS phase I trial

✍ Scribed by Jaremtchuk, A.V.; Zabra, J.J.; Ferro, A.; Aman, E.F.; Alvarez, R.; Arroyo, G.; Marmissolle, F.

Book ID
122608833
Publisher
Elsevier Science
Year
1999
Tongue
English
Weight
144 KB
Volume
35
Category
Article
ISSN
0959-8049

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A phase I study of gemcitabine and docet
A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors
✍ David P. Ryan; Thomas J. Lynch; Michael L. Grossbard; Michael V. Seiden; Charles πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 70 KB πŸ‘ 2 views

A Phase I study was initiated to determine the maximum tolerated dose of weekly gemcitabine combined with monthly, fixed-dose docetaxel. ## METHODS. Patients with metastatic solid tumors were treated with docetaxel, 60 mg/m 2 , on Day 1 every 28 days. Gemcitabine was administered on Days 1, 8, and

Phase I clinical trial of bortezomib in
Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors
✍ David P. Ryan; Leonard J. Appleman; Thomas Lynch; Jeffrey G. Supko; Panagiotis F πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 114 KB πŸ‘ 2 views

## Abstract ## BACKGROUND. Bortezomib is the first proteasome inhibitor to show preliminary evidence of activity against solid tumors. Findings from preclinical studies prompted a Phase I trial to determine the maximum tolerated dose (MTD) and dose‐limiting toxicities (DLTs) of bortezomib in combi